{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T14:51:01Z","timestamp":1788187861298,"version":"build-2803163510"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01299-3","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:18:23Z","timestamp":1763745503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Immunogenicity and efficacy of homologous and heterologous NDV and MVA SARS-CoV-2 vaccines in mice and hamsters"],"prefix":"10.1038","volume":"10","author":[{"given":"Patricia","family":"P\u00e9rez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaijun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Rodr\u00edguez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Abdeljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasija","family":"Cupic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Slamanig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A.","family":"Noriega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro J.","family":"S\u00e1nchez-Cord\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsoi Ying","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"Garc\u00eda-Sastre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Arriaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch, D. H. Covid-19 Vaccines - Immunity, Variants, Boosters. N. Engl. J. Med 387, 1011\u20131020, https:\/\/doi.org\/10.1056\/NEJMra2206573 (2022).","journal-title":"N. Engl. J. Med"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"e252223","DOI":"10.1001\/jamahealthforum.2025.2223","volume":"6","author":"JPA Ioannidis","year":"2025","unstructured":"Ioannidis, J. P. A., Pezzullo, A. M., Cristiano, A. & Boccia, S. Global Estimates of Lives and Life-Years Saved by COVID-19 Vaccination During 2020-2024. JAMA Health Forum 6, e252223, https:\/\/doi.org\/10.1001\/jamahealthforum.2025.2223 (2025).","journal-title":"JAMA Health Forum"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/22221751.2021.1902245","volume":"10","author":"Q He","year":"2021","unstructured":"He, Q. et al. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates. Emerg. Microbes Infect. 10, 629\u2013637, https:\/\/doi.org\/10.1080\/22221751.2021.1902245 (2021).","journal-title":"Emerg. Microbes Infect."},{"key":"1299_CR4","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","volume":"399","author":"SA Costa Clemens","year":"2022","unstructured":"Costa Clemens, S. A. et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet 399, 521\u2013529, https:\/\/doi.org\/10.1016\/S0140-6736(22)00094-0 (2022).","journal-title":"Lancet"},{"key":"1299_CR5","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3390\/vaccines10050649","volume":"10","author":"RDH Markewitz","year":"2022","unstructured":"Markewitz, R. D. H. et al. Differences in Immunogenicity of Three Different Homo- and Heterologous Vaccination Regimens against SARS-CoV-2. Vaccines (Basel) 10, 649, https:\/\/doi.org\/10.3390\/vaccines10050649 (2022).","journal-title":"Vaccines (Basel)"},{"key":"1299_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-022-00503-y","volume":"7","author":"T Travieso","year":"2022","unstructured":"Travieso, T., Li, J., Mahesh, S., Mello, J. & Blasi, M. The use of viral vectors in vaccine development. NPJ Vaccines 7, 75. https:\/\/doi.org\/10.1038\/s41541-022-00503-y (2022).","journal-title":"NPJ Vaccines"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/v15010204","volume":"15","author":"E Sallard","year":"2023","unstructured":"Sallard, E., Zhang, W., Aydin, M., Schroer, K. & Ehrhardt, A. The Adenovirus Vector Platform: Novel Insights into Rational Vector Design and Lessons Learned from the COVID-19 Vaccine. Viruses 15, 204, https:\/\/doi.org\/10.3390\/v15010204 (2023).","journal-title":"Viruses"},{"key":"1299_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01538-22","volume":"10","author":"I Gonzalez-Dominguez","year":"2022","unstructured":"Gonzalez-Dominguez, I. et al. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. Microbiol Spectr. 10, e0153822. https:\/\/doi.org\/10.1128\/spectrum.01538-22 (2022).","journal-title":"Microbiol Spectr."},{"key":"1299_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105185","volume":"105","author":"S Slamanig","year":"2024","unstructured":"Slamanig, S. et al. Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. EBioMedicine 105, 105185. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105185 (2024).","journal-title":"EBioMedicine"},{"key":"1299_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26499-y","volume":"12","author":"W Sun","year":"2021","unstructured":"Sun, W. et al. A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. Nat. Commun. 12, 6197. https:\/\/doi.org\/10.1038\/s41467-021-26499-y (2021).","journal-title":"Nat. Commun."},{"key":"1299_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.791764","volume":"12","author":"J Tcheou","year":"2021","unstructured":"Tcheou, J. et al. Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. Front Immunol. 12, 791764. https:\/\/doi.org\/10.3389\/fimmu.2021.791764 (2021).","journal-title":"Front Immunol."},{"key":"1299_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1163159","volume":"14","author":"R Abdelnabi","year":"2023","unstructured":"Abdelnabi, R. et al. Optimized vaccine candidate MVA-S(3P) fully protects against SARS-CoV-2 infection in hamsters. Front Immunol. 14, 1163159. https:\/\/doi.org\/10.3389\/fimmu.2023.1163159 (2023).","journal-title":"Front Immunol."},{"key":"1299_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264323","volume":"14","author":"P Perez","year":"2023","unstructured":"Perez, P. et al. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates. Front Immunol. 14, 1264323. https:\/\/doi.org\/10.3389\/fimmu.2023.1264323 (2023).","journal-title":"Front Immunol."},{"key":"1299_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995235","volume":"13","author":"P Perez","year":"2022","unstructured":"Perez, P. et al. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection. Front Immunol. 13, 995235. https:\/\/doi.org\/10.3389\/fimmu.2022.995235 (2022).","journal-title":"Front Immunol."},{"key":"1299_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1420304","volume":"15","author":"P Perez","year":"2024","unstructured":"Perez, P. et al. MVA-based vaccine candidates expressing SARS-CoV-2 prefusion-stabilized spike proteins of the Wuhan, Beta or Omicron BA.1 variants protect transgenic K18-hACE2 mice against Omicron infection and elicit robust and broad specific humoral and cellular immune responses. Front Immunol. 15, 1420304. https:\/\/doi.org\/10.3389\/fimmu.2024.1420304 (2024).","journal-title":"Front Immunol."},{"key":"1299_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.824728","volume":"12","author":"P Perez","year":"2022","unstructured":"Perez, P. et al. A Single Dose of an MVA Vaccine Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Protein Neutralizes Variants of Concern and Protects Mice From a Lethal SARS-CoV-2 Infection. Front Immunol. 12, 824728. https:\/\/doi.org\/10.3389\/fimmu.2021.824728 (2022).","journal-title":"Front Immunol."},{"key":"1299_CR17","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.1016\/j.vaccine.2022.04.078","volume":"40","author":"A Duc Dang","year":"2022","unstructured":"Duc Dang, A. et al. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1\/2 trial in Vietnam. Vaccine 40, 3621\u20133632, https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.078 (2022).","journal-title":"Vaccine"},{"key":"1299_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126511","volume":"43","author":"C L\u00f3pez-Mac\u00edas","year":"2025","unstructured":"L\u00f3pez-Mac\u00edas, C. et al. Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX\/COVID-12 \u201cPatria\u201d recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in Mexico. Vaccine 43, 126511 (2025).","journal-title":"Vaccine"},{"key":"1299_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101323","volume":"45","author":"P Pitisuttithum","year":"2022","unstructured":"Pitisuttithum, P. et al. Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. EClinicalMedicine 45, 101323. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101323 (2022).","journal-title":"EClinicalMedicine"},{"key":"1299_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00662-6","volume":"8","author":"S Ponce-de-Leon","year":"2023","unstructured":"Ponce-de-Leon, S. et al. Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico. NPJ Vaccines 8, 67. https:\/\/doi.org\/10.1038\/s41541-023-00662-6 (2023).","journal-title":"NPJ Vaccines"},{"key":"1299_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-21630-4","volume":"8","author":"CM Bliss","year":"2018","unstructured":"Bliss, C. M. et al. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP. Sci. Rep. 8, 3390. https:\/\/doi.org\/10.1038\/s41598-018-21630-4 (2018).","journal-title":"Sci. Rep."},{"key":"1299_CR22","doi-asserted-by":"publisher","unstructured":"Tang, J., Amin, M. A. & Campian, J. L. Past, Present, and Future of Viral Vector Vaccine Platforms: A Comprehensive Review. Vaccines (Basel) 13, https:\/\/doi.org\/10.3390\/vaccines13050524 (2025).","DOI":"10.3390\/vaccines13050524"},{"key":"1299_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00833-z","volume":"9","author":"M Happe","year":"2024","unstructured":"Happe, M. et al. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1\/1b trials. NPJ Vaccines 9, 67. https:\/\/doi.org\/10.1038\/s41541-024-00833-z (2024).","journal-title":"NPJ Vaccines"},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/infdis\/jiy639","volume":"219","author":"N Venkatraman","year":"2019","unstructured":"Venkatraman, N. et al. Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal. J. Infect. Dis. 219, 1187\u20131197, https:\/\/doi.org\/10.1093\/infdis\/jiy639 (2019).","journal-title":"J. Infect. Dis."},{"key":"1299_CR25","doi-asserted-by":"publisher","first-page":"449","DOI":"10.4049\/jimmunol.174.1.449","volume":"174","author":"JM Vuola","year":"2005","unstructured":"Vuola, J. M. et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol. 174, 449\u2013455, https:\/\/doi.org\/10.4049\/jimmunol.174.1.449 (2005).","journal-title":"J. Immunol."},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1016\/j.idnow.2022.09.011","volume":"52","author":"O Launay","year":"2022","unstructured":"Launay, O. & Thill, P. Heterologous prime boost COVID 19 vaccination. Infect. Dis. Now. 52, S7\u2013S8, https:\/\/doi.org\/10.1016\/j.idnow.2022.09.011 (2022).","journal-title":"Infect. Dis. Now."},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.coi.2009.05.016","volume":"21","author":"S Lu","year":"2009","unstructured":"Lu, S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21, 346\u2013351, https:\/\/doi.org\/10.1016\/j.coi.2009.05.016 (2009).","journal-title":"Curr. Opin. Immunol."},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1126\/science.1531159","volume":"255","author":"SL Hu","year":"1992","unstructured":"Hu, S. L. et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255, 456\u2013459, https:\/\/doi.org\/10.1126\/science.1531159 (1992).","journal-title":"Science"},{"key":"1299_CR29","doi-asserted-by":"publisher","first-page":"5214","DOI":"10.1073\/pnas.90.11.5214","volume":"90","author":"S Li","year":"1993","unstructured":"Li, S. et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 90, 5214\u20135218, https:\/\/doi.org\/10.1073\/pnas.90.11.5214 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3390\/vaccines10050798","volume":"10","author":"H Cheng","year":"2022","unstructured":"Cheng, H. et al. Immunogenicity and Safety of Homologous and Heterologous Prime-Boost Immunization with COVID-19 Vaccine: Systematic Review and Meta-Analysis. Vaccines (Basel) 10, 798, https:\/\/doi.org\/10.3390\/vaccines10050798 (2022).","journal-title":"Vaccines (Basel)"},{"key":"1299_CR31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3390\/idr14040057","volume":"14","author":"I Garg","year":"2022","unstructured":"Garg, I., Sheikh, A. B., Pal, S. & Shekhar, R. Mix-and-Match COVID-19 Vaccinations (Heterologous Boost): A Review. Infect. Dis. Rep. 14, 537\u2013546, https:\/\/doi.org\/10.3390\/idr14040057 (2022).","journal-title":"Infect. Dis. Rep."},{"key":"1299_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1062210","volume":"13","author":"N Heinen","year":"2022","unstructured":"Heinen, N. et al. In-depth analysis of T cell immunity and antibody responses in heterologous prime-boost-boost vaccine regimens against SARS-CoV-2 and Omicron variant. Front Immunol. 13, 1062210. https:\/\/doi.org\/10.3389\/fimmu.2022.1062210 (2022).","journal-title":"Front Immunol."},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"e0003260","DOI":"10.1371\/journal.pgph.0003260","volume":"4","author":"N Garrett","year":"2024","unstructured":"Garrett, N. et al. Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa: The single-arm, open-label, phase 3 SHERPA study. PLOS Glob. Public Health 4, e0003260, https:\/\/doi.org\/10.1371\/journal.pgph.0003260 (2024).","journal-title":"PLOS Glob. Public Health"},{"key":"1299_CR34","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1016\/j.ymthe.2024.10.016","volume":"32","author":"G Laghlali","year":"2024","unstructured":"Laghlali, G. et al. Enhanced mucosal SARS-CoV-2 immunity after heterologous intramuscular mRNA prime\/intranasal protein boost vaccination with a combination adjuvant. Mol. Ther. 32, 4448\u20134466, https:\/\/doi.org\/10.1016\/j.ymthe.2024.10.016 (2024).","journal-title":"Mol. Ther."},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41421-021-00360-4","volume":"7","author":"J Liu","year":"2021","unstructured":"Liu, J. et al. Heterologous prime-boost immunizations with chimpanzee adenoviral vectors elicit potent and protective immunity against SARS-CoV-2 infection. Cell Discov. 7, 123, https:\/\/doi.org\/10.1038\/s41421-021-00360-4 (2021).","journal-title":"Cell Discov."},{"key":"1299_CR36","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.vaccine.2008.01.016","volume":"26","author":"J Veits","year":"2008","unstructured":"Veits, J. et al. Protective efficacy of several vaccines against highly pathogenic H5N1 avian influenza virus under experimental conditions. Vaccine 26, 1688\u20131696, https:\/\/doi.org\/10.1016\/j.vaccine.2008.01.016 (2008).","journal-title":"Vaccine"},{"key":"1299_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/srep36840","volume":"6","author":"M Olbert","year":"2016","unstructured":"Olbert, M. et al. Viral vector vaccines expressing nucleoprotein and phosphoprotein genes of avian bornaviruses ameliorate homologous challenge infections in cockatiels and common canaries. Sci. Rep. 6, 36840. https:\/\/doi.org\/10.1038\/srep36840 (2016).","journal-title":"Sci. Rep."},{"key":"1299_CR38","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.vaccine.2016.12.022","volume":"35","author":"S Runge","year":"2017","unstructured":"Runge, S. et al. Viral vector vaccines protect cockatiels from inflammatory lesions after heterologous parrot bornavirus 2 challenge infection. Vaccine 35, 557\u2013563, https:\/\/doi.org\/10.1016\/j.vaccine.2016.12.022 (2017).","journal-title":"Vaccine"},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.3390\/v11121130","volume":"11","author":"I Rall","year":"2019","unstructured":"Rall, I., Amann, R., Malberg, S., Herden, C. & Rubbenstroth, D. Recombinant Modified Vaccinia Virus Ankara (MVA) Vaccines Efficiently Protect Cockatiels Against Parrot Bornavirus Infection and Proventricular Dilatation Disease. Viruses 11, 1130, https:\/\/doi.org\/10.3390\/v11121130 (2019).","journal-title":"Viruses"},{"key":"1299_CR40","doi-asserted-by":"publisher","unstructured":"Koch, T., Mellinghoff, S. C., Shamsrizi, P., Addo, M. M. & Dahlke, C. Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9030238 (2021).","DOI":"10.3390\/vaccines9030238"},{"key":"1299_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2387906","volume":"13","author":"L Marcos-Villar","year":"2024","unstructured":"Marcos-Villar, L. et al. Heterologous mRNA\/MVA delivering trimeric-RBD as effective vaccination regimen against SARS-CoV-2: COVARNA Consortium. Emerg. Microbes Infect. 13, 2387906. https:\/\/doi.org\/10.1080\/22221751.2024.2387906 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1299_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00838-8","volume":"9","author":"L Marcos-Villar","year":"2024","unstructured":"Marcos-Villar, L. et al. Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium. NPJ Vaccines 9, 53. https:\/\/doi.org\/10.1038\/s41541-024-00838-8 (2024).","journal-title":"NPJ Vaccines"},{"key":"1299_CR43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo2847","volume":"15","author":"JM Carreno","year":"2023","unstructured":"Carreno, J. M. et al. An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination. Sci. Transl. Med 15, eabo2847. https:\/\/doi.org\/10.1126\/scitranslmed.abo2847 (2023).","journal-title":"Sci. Transl. Med"},{"key":"1299_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adp1290","volume":"10","author":"TL Darling","year":"2024","unstructured":"Darling, T. L. et al. Mucosal immunization with ChAd-SARS-CoV-2-S prevents sequential transmission of SARS-CoV-2 to unvaccinated hamsters. Sci. Adv. 10, eadp1290. https:\/\/doi.org\/10.1126\/sciadv.adp1290 (2024).","journal-title":"Sci. Adv."},{"key":"1299_CR45","doi-asserted-by":"publisher","first-page":"222","DOI":"10.3389\/fimmu.2013.00222","volume":"4","author":"P Brandtzaeg","year":"2013","unstructured":"Brandtzaeg, P. Secretory IgA: Designed for Anti-Microbial Defense. Front Immunol. 4, 222, https:\/\/doi.org\/10.3389\/fimmu.2013.00222 (2013).","journal-title":"Front Immunol."},{"key":"1299_CR46","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev.immunol.22.012703.104702","volume":"22","author":"F Sallusto","year":"2004","unstructured":"Sallusto, F., Geginat, J. & Lanzavecchia, A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev. Immunol. 22, 745\u2013763, https:\/\/doi.org\/10.1146\/annurev.immunol.22.012703.104702 (2004).","journal-title":"Annu Rev. Immunol."},{"key":"1299_CR47","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1016\/j.drudis.2021.07.021","volume":"26","author":"VP Chavda","year":"2021","unstructured":"Chavda, V. P., Vora, L. K., Pandya, A. K. & Patravale, V. B. Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management. Drug Discov. Today 26, 2619\u20132636, https:\/\/doi.org\/10.1016\/j.drudis.2021.07.021 (2021).","journal-title":"Drug Discov. Today"},{"key":"1299_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2023.101348","volume":"62","author":"RL de Swart","year":"2023","unstructured":"de Swart, R. L. & Belov, G. A. Advantages and challenges of Newcastle disease virus as a vector for respiratory mucosal vaccines. Curr. Opin. Virol. 62, 101348. https:\/\/doi.org\/10.1016\/j.coviro.2023.101348 (2023).","journal-title":"Curr. Opin. Virol."},{"key":"1299_CR49","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1016\/j.vaccine.2022.07.005","volume":"40","author":"RL de Swart","year":"2022","unstructured":"de Swart, R. L. et al. Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental challenge infection in hamsters. Vaccine 40, 4676\u20134681, https:\/\/doi.org\/10.1016\/j.vaccine.2022.07.005 (2022).","journal-title":"Vaccine"},{"key":"1299_CR50","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/vaccines12040404","volume":"12","author":"BM Warner","year":"2024","unstructured":"Warner, B. M. et al. Mucosal Vaccination with a Newcastle Disease Virus-Vectored Vaccine Reduces Viral Loads in SARS-CoV-2-Infected Cynomolgus Macaques. Vaccines (Basel) 12, 404, https:\/\/doi.org\/10.3390\/vaccines12040404 (2024).","journal-title":"Vaccines (Basel)"},{"key":"1299_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1524477","volume":"16","author":"I Gonzalez-Dominguez","year":"2025","unstructured":"Gonzalez-Dominguez, I. et al. Mucosal multivalent NDV-based vaccine provides cross-reactive immune responses against SARS-CoV-2 variants in animal models. Front Immunol. 16, 1524477. https:\/\/doi.org\/10.3389\/fimmu.2025.1524477 (2025).","journal-title":"Front Immunol."},{"key":"1299_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25156-8","volume":"12","author":"JR Port","year":"2021","unstructured":"Port, J. R. et al. SARS-CoV-2 disease severity and transmission efficiency is increased for airborne compared to fomite exposure in Syrian hamsters. Nat. Commun. 12, 4985. https:\/\/doi.org\/10.1038\/s41467-021-25156-8 (2021).","journal-title":"Nat. Commun."},{"key":"1299_CR53","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838, https:\/\/doi.org\/10.1038\/s41586-020-2342-5 (2020).","journal-title":"Nature"},{"key":"1299_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104248","volume":"84","author":"D Christensen","year":"2022","unstructured":"Christensen, D. et al. Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy. EBioMedicine 84, 104248. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104248 (2022).","journal-title":"EBioMedicine"},{"key":"1299_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42346-8","volume":"14","author":"JR Port","year":"2023","unstructured":"Port, J. R. et al. Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters. Nat. Commun. 14, 6592. https:\/\/doi.org\/10.1038\/s41467-023-42346-8 (2023).","journal-title":"Nat. Commun."},{"key":"1299_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611337","volume":"11","author":"MW Russell","year":"2020","unstructured":"Russell, M. W., Moldoveanu, Z., Ogra, P. L. & Mestecky, J. Mucosal Immunity in COVID-19: A Neglected but Critical Aspect of SARS-CoV-2 Infection. Front Immunol. 11, 611337. https:\/\/doi.org\/10.3389\/fimmu.2020.611337 (2020).","journal-title":"Front Immunol."},{"key":"1299_CR57","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nri3251","volume":"12","author":"N Lycke","year":"2012","unstructured":"Lycke, N. Recent progress in mucosal vaccine development: potential and limitations. Nat. Rev. Immunol. 12, 592\u2013605, https:\/\/doi.org\/10.1038\/nri3251 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"1299_CR58","doi-asserted-by":"publisher","first-page":"6883","DOI":"10.4049\/jimmunol.0901466","volume":"183","author":"IM Belyakov","year":"2009","unstructured":"Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens?. J. Immunol. 183, 6883\u20136892, https:\/\/doi.org\/10.4049\/jimmunol.0901466 (2009).","journal-title":"J. Immunol."},{"key":"1299_CR59","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri2496","volume":"9","author":"DL Woodland","year":"2009","unstructured":"Woodland, D. L. & Kohlmeier, J. E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat. Rev. Immunol. 9, 153\u2013161, https:\/\/doi.org\/10.1038\/nri2496 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"1299_CR60","doi-asserted-by":"publisher","first-page":"191","DOI":"10.3390\/vaccines12020191","volume":"12","author":"Y Song","year":"2024","unstructured":"Song, Y., Mehl, F. & Zeichner, S. L. Vaccine Strategies to Elicit Mucosal Immunity. Vaccines (Basel) 12, 191, https:\/\/doi.org\/10.3390\/vaccines12020191 (2024).","journal-title":"Vaccines (Basel)"},{"key":"1299_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105757","volume":"220","author":"QY Zhang","year":"2023","unstructured":"Zhang, Q. Y. et al. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization. Antivir. Res 220, 105757. https:\/\/doi.org\/10.1016\/j.antiviral.2023.105757 (2023).","journal-title":"Antivir. Res"},{"key":"1299_CR62","first-page":"464","volume":"128","author":"A Volz","year":"2015","unstructured":"Volz, A., Fux, R., Langenmayer, M. C. & Sutter, G. Modified vaccinia virus ankara (MVA)\u2013development as recombinant vaccine and prospects for use in veterinary medicine]. Berl. Munch. Tierarzt. Wochenschr. 128, 464\u2013472 (2015).","journal-title":"Berl. Munch. Tierarzt. Wochenschr."},{"key":"1299_CR63","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3390\/v6072735","volume":"6","author":"AF Altenburg","year":"2014","unstructured":"Altenburg, A. F. et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses 6, 2735\u20132761, https:\/\/doi.org\/10.3390\/v6072735 (2014).","journal-title":"Viruses"},{"key":"1299_CR64","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1073\/pnas.95.7.3954","volume":"95","author":"Y Miyahira","year":"1998","unstructured":"Miyahira, Y. et al. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc. Natl Acad. Sci. USA 95, 3954\u20133959, https:\/\/doi.org\/10.1073\/pnas.95.7.3954 (1998).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1299_CR65","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1006\/cimm.1996.0255","volume":"173","author":"K Murata","year":"1996","unstructured":"Murata, K. et al. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 173, 96\u2013107, https:\/\/doi.org\/10.1006\/cimm.1996.0255 (1996).","journal-title":"Cell Immunol."},{"key":"1299_CR66","doi-asserted-by":"publisher","first-page":"4636","DOI":"10.4049\/jimmunol.153.10.4636","volume":"153","author":"M Rodrigues","year":"1994","unstructured":"Rodrigues, M. et al. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J. Immunol. 153, 4636\u20134648 (1994).","journal-title":"J. Immunol."},{"key":"1299_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168173","volume":"435","author":"B Perdiguero","year":"2023","unstructured":"Perdiguero, B. et al. Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases. J. Mol. Biol. 435, 168173. https:\/\/doi.org\/10.1016\/j.jmb.2023.168173 (2023).","journal-title":"J. Mol. Biol."},{"key":"1299_CR68","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41593-022-01242-y","volume":"26","author":"J Villadiego","year":"2023","unstructured":"Villadiego, J. et al. Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. Nat. Neurosci. 26, 226\u2013238, https:\/\/doi.org\/10.1038\/s41593-022-01242-y (2023).","journal-title":"Nat. Neurosci."},{"key":"1299_CR69","first-page":"375","volume":"167","author":"A Mayr","year":"1978","unstructured":"Mayr, A., Stickl, H., Muller, H. K., Danner, K. & Singer, H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)]. Zentralbl Bakteriol. B 167, 375\u2013390 (1978).","journal-title":"Zentralbl Bakteriol. B"},{"key":"1299_CR70","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1128\/jvi.74.2.923-933.2000","volume":"74","author":"JC Ramirez","year":"2000","unstructured":"Ramirez, J. C., Gherardi, M. M. & Esteban, M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74, 923\u2013933, https:\/\/doi.org\/10.1128\/jvi.74.2.923-933.2000 (2000).","journal-title":"J. Virol."},{"key":"1299_CR71","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.2217\/imt-2020-0220","volume":"12","author":"JM Diez","year":"2020","unstructured":"Diez, J. M. et al. Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins. Immunotherapy 12, 1247\u20131255, https:\/\/doi.org\/10.2217\/imt-2020-0220 (2020).","journal-title":"Immunotherapy"},{"key":"1299_CR72","doi-asserted-by":"publisher","first-page":"2000045","DOI":"10.2807\/1560-7917.ES.2020.25.3.2000045","volume":"25","author":"VM Corman","year":"2020","unstructured":"Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur. Surveill. 25, 2000045, https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.3.2000045 (2020).","journal-title":"Eur. Surveill."},{"key":"1299_CR73","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.chom.2020.05.020","volume":"28","author":"SH Sun","year":"2020","unstructured":"Sun, S. H. et al. A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. Cell Host Microbe 28, 124\u2013133.e124, https:\/\/doi.org\/10.1016\/j.chom.2020.05.020 (2020).","journal-title":"Cell Host Microbe"},{"key":"1299_CR74","doi-asserted-by":"publisher","first-page":"e02260","DOI":"10.1128\/JVI.02260-20","volume":"95","author":"J Garcia-Arriaza","year":"2021","unstructured":"Garcia-Arriaza, J. et al. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice. J. Virol. 95, e02260\u201302220, https:\/\/doi.org\/10.1128\/JVI.02260-20 (2021).","journal-title":"J. Virol."},{"key":"1299_CR75","doi-asserted-by":"publisher","first-page":"e02370","DOI":"10.1128\/JVI.02370-20","volume":"95","author":"G Dagotto","year":"2021","unstructured":"Dagotto, G. et al. Comparison of Subgenomic and Total RNA in SARS-CoV-2 Challenged Rhesus Macaques. J. Virol. 95, e02370\u201302320, https:\/\/doi.org\/10.1128\/JVI.02370-20 (2021).","journal-title":"J. Virol."},{"key":"1299_CR76","doi-asserted-by":"publisher","first-page":"e12395","DOI":"10.1371\/journal.pone.0012395","volume":"5","author":"J Garcia-Arriaza","year":"2010","unstructured":"Garcia-Arriaza, J., Najera, J. L., Gomez, C. E., Sorzano, C. O. & Esteban, M. Immunogenic profiling in mice of a HIV\/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions. PLoS One 5, e12395, https:\/\/doi.org\/10.1371\/journal.pone.0012395 (2010).","journal-title":"PLoS One"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01299-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01299-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:18:24Z","timestamp":1763745504000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01299-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01299-3","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The A.G.-S. laboratory has received research support from GSK, Pfizer, Senhwa Biosciences, Kenall Manufacturing, Blade Therapeutics, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma, Applied Biological Laboratories and Merck. A.G.-S. has consulting agreements for the following companies involving cash and\/or stock: Castlevax, Amovir, Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Pagoda, Accurius, Esperovax, Applied Biological Laboratories, Pharmamar, CureLab Oncology, CureLab Veterinary, Synairgen, Paratus, Pfizer, Virofend and Prosetta. A.G.-S. has been an invited speaker in meeting events organized by Seqirus, Janssen, Abbott, Astrazeneca and Novavax. A.G.-S. is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the ISMMS, New York. ISMMS has filed patent application entitled \u201cRecombinant Newcastle disease virus expressing SARS-COV-2 spike protein and uses thereof\u201d which names A.G.-S. and W.S. as co-inventors. A.G.-S. and W.S. serve on the scientific advisory board of CastleVax and are listed as co-founders of the company. The rest of the authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"246"}}